TY - JOUR T1 - Growth Differentiation Factor-15 as a candidate biomarker in gynecologic malignancies: a meta-analysis JF - medRxiv DO - 10.1101/2020.07.07.20148221 SP - 2020.07.07.20148221 AU - Dipayan Roy AU - Purvi Purohit AU - Anupama Modi AU - Manoj Khokhar AU - Manu Goyal AU - Puneet Setia AU - Shailja Sharma AU - Praveen Sharma AU - Facciorusso Antonio Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/08/2020.07.07.20148221.abstract N2 - Introduction Growth Differentiation Factor-15 (GDF-15) has emerged as a novel marker in gyne-cological cancers. But its suitability in clinical diagnostics is yet to be recognized.Materials and methods We sorted out eligible studies from multiple online databases like Pubmed, Cochrane, ClinicalTrials.gov, Google Scholar, Web of Science, Embase, Scopus, LILACS, and Opengrey. The terms used were ‘Growth Differentiation Factor-15’, ‘GDF-15’, ‘Macrophage Inhibitory Cytokine-1’, ‘MIC-1’, ‘Ovarian cancer’, ‘Ovarian carcinoma’, ‘Endometrial cancer’, ‘Endometrial carcinoma’, ‘Uterine cancer’, ‘Uterine Carcinoma’, ‘Cervical cancer’, ‘Cervical car-cinoma’, ‘diagnosis’, ‘sensitivity’, ‘specificity’, ‘prognosis’, and ‘outcome’. Of the full-text, potentially eligible records, six were found eligible for inclusion into our meta-analysis. Studies were selected only if the diagnosis was proven by pathology, cases recruited were those without any prior treatment, sufficient diagnostic accuracy data were present for GDF-15 in gynecological cancers, ethical approval was taken from Institutional Ethics Committee, and full-text material was available in English. Nonclinical research and animal studies were excluded. We took the assistance of the Rayyan QCRI software for the screening and selection process. We conducted the study following Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines and used Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) to assess the risk of bias.The protocol was registered at PROSPERO, registration number CRD42019130097.Results We extracted diagnostic accuracy data from the articles and evaluated the role of GDF-15 by pooling the sensitivity, specificity, and diagnostic odds ratio (DOR) and plotting a summary receiver operating characteristic (SROC) curve. Since there was heterogeneity across the studies, random-effects model was employed to carry out the integration. The meta-analysis showed that GDF-15 has a pooled DOR of 12.74 at 80.5% sensitivity and 74.1% specificity, with an area under the curve (AUC) of 0.84.Conclusion Our analysis suggests that GDF-15 may be a useful candidate marker to differentiate malignant from non-malignant tumors of the female reproductive system.Registration detail: PROSPERO, CRD42019130097.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee (IEC), All India Institute of Medical Sciences (AIIMS), JodhpurAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable. ER -